Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 through 64 Years of Age

Trial Identifier: QHD00042
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: November 2024
Primary Completion Date: January 2025
Study Completion Date: June 2025
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
United States, California LOS ALAMITOS, California, United States, 90720
United States, Florida Fort Myers, Florida, United States, 33912
United States, Florida HOLLYWOOD, Florida, United States, 33024
United States, Georgia COLUMBUS, Georgia, United States, 31904
United States, Georgia DECATUR, Georgia, United States, 30030
United States, Georgia RINCON, Georgia, United States, 31406
United States, Georgia SAVANNAH, Georgia, United States, 31405
United States, Kansas NEWTON, Kansas, United States, 67114
United States, Kentucky LEXINGTON, Kentucky, United States, 40509
United States, Maryland GAITHERSBURG, Maryland, United States, 20877
United States, New Jersey BERLIN, New Jersey, United States, 08009
United States, North Carolina Morehead City, North Carolina, United States, 28557
United States, North Carolina NEW BERN, North Carolina, United States, 28562
United States, Ohio COLUMBUS, Ohio, United States, 43213
United States, Oregon PORTLAND, Oregon, United States, 97227
United States, Tennessee KNOXVILLE, Tennessee, United States, 37920
United States, Utah SALT LAKE CITY, Utah, United States, 84107
United States, Virginia SUFFOLK, Virginia, United States, 23435-3763
United States, Washington SEATTLE, Washington, United States, 98101